share_log

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Down 16.7% in September

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Down 16.7% in September

基奧拉制藥公司(納斯達克代碼:KPRX)空頭股數9月份下跌16.7%
Financial News Live ·  2022/10/02 15:51

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 5,900,000 shares, a decrease of 16.7% from the August 31st total of 7,080,000 shares. Based on an average daily trading volume, of 10,560,000 shares, the short-interest ratio is currently 0.6 days.

Kiora製藥公司(納斯達克:KPRX-GET評級)是空頭股數9月份大幅下跌的目標。截至9月15日,空頭股數共有590萬股,比8月31日的708萬股減少了16.7%。以日均成交量一萬零五十六萬股計算,目前短息比率為零點六天。

Institutional Investors Weigh In On Kiora Pharmaceuticals

機構投資者看好Kiora製藥公司

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Renaissance Technologies LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 93,619 shares of the company's stock, valued at approximately $58,000. Renaissance Technologies LLC owned about 0.74% of Kiora Pharmaceuticals as of its most recent filing with the SEC. 30.61% of the stock is owned by institutional investors and hedge funds.

一家對衝基金最近購買了Kiora PharmPharmticals股票的新股份。根據復興科技有限公司在最近提交給美國證券交易委員會的文件中,該公司在第一季度購買了Kiora製藥公司(KPRX:KPRX-GET評級)的新股。該機構投資者購買了93,619股該公司股票,價值約58,000美元。截至最近向美國證券交易委員會提交的文件,復興科技持有Kiora PharmPharmticals約0.74%的股份。30.61%的股票由機構投資者和對衝基金持有。

Get
到達
Kiora Pharmaceuticals
Kiora製藥公司
alerts:
警報:

Kiora Pharmaceuticals Stock Performance

Kiora製藥公司股票表現

Shares of KPRX traded down $0.57 on Friday, reaching $6.15. The stock had a trading volume of 258,453 shares, compared to its average volume of 317,538. The firm has a 50-day moving average of $12.25 and a 200 day moving average of $16.61. Kiora Pharmaceuticals has a twelve month low of $4.86 and a twelve month high of $92.00.

KPRX股價週五下跌0.57美元,至6.15美元。該股成交量為258,453股,而其平均成交量為317,538股。該公司的50日移動均線切入位在12.25美元,200日移動均線切入位在16.61美元。Kiora PharmPharmticals的12個月低點為4.86美元,12個月高位為92.00美元。

Kiora Pharmaceuticals (NASDAQ:KPRX – Get Rating) last released its quarterly earnings results on Friday, July 8th. The company reported ($10.80) earnings per share for the quarter. As a group, equities analysts anticipate that Kiora Pharmaceuticals will post -17.6 EPS for the current fiscal year.
Kiora製藥(納斯達克:KPRX-GET評級)最近一次發佈季度收益報告是在7月8日(星期五)。該公司公佈了本季度每股收益(10.80美元)。股票分析師預計,Kiora製藥公司本財年的每股收益將達到17.6美元。

Analysts Set New Price Targets

分析師設定新的價格目標

A number of equities analysts have recently issued reports on KPRX shares. HC Wainwright cut their target price on Kiora Pharmaceuticals from $120.00 to $100.00 and set a "buy" rating for the company in a research note on Monday, July 11th. LADENBURG THALM/SH SH initiated coverage on Kiora Pharmaceuticals in a report on Thursday, August 25th. They issued a "buy" rating on the stock. Finally, Maxim Group cut Kiora Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, August 15th.

一些股票分析師最近發佈了關於KPRX股票的報告。7月11日,週一,HC Wainwright在一份研究報告中將Kiora PharmPharmticals的目標價從120.00美元下調至100.00美元,併為該公司設定了“買入”評級。拉登堡THALM/SH在8月25日星期四的一份報告中啟動了對Kiora製藥的報道。他們對該股的評級為“買入”。最後,Maxim Group在8月15日週一的一份報告中將Kiora PharmPharmticals的評級從“買入”下調至“持有”。

About Kiora Pharmaceuticals

Kiora製藥公司簡介

(Get Rating)

(獲取評級)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.

Kiora製藥公司是一家臨牀階段的專業製藥公司,在美國開發和銷售治療眼科疾病的療法。它的主要產品是KIO-301,這是一種潛在的恢復視力的小分子,正在進行一期臨牀試驗,作為一種光開關來恢復遺傳性和年齡相關的退行性視網膜疾病患者的視力。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Kiora Pharmaceuticals (KPRX)
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • This Is A Memorable Time To Buy Into Micron Technology
  • Declining Profits Challenge the CarMax Value Proposition
  • How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
  • 免費獲取StockNews.com關於Kiora製藥公司的研究報告(KPRX)
  • 電動汽車電池製造商Freyr將在全球大舉擴張
  • MarketBeat:回顧一週9/26-9/30
  • 這是買入美光科技的難忘時刻
  • 利潤下降對CarMax價值主張的挑戰
  • Keurig Dr Pepper與規模更大的競爭對手可口可樂(Coke&Pepsi)相比如何?

Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

獲得Kiora製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Kiora製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論